Pharmacological action

Antiaggregant drug. Specific and active inhibitor of platelet aggregation. Selectively reduces the binding of adenosine diphosphate (ADP) to platelet receptors and the activation of GPI Ib / IIIa receptors under the action of ADP, thereby weakening platelet aggregation.

Reduces platelet aggregation, caused by other agonists, preventing their activation by released ADP, does not affect the activity of phosphodiesterase (PDE).

Irreversibly binds to ADP-receptor platelets, which remain immune to stimulation of ADP throughout the life cycle (about 7 days). The inhibition of platelet aggregation is observed after 2 hours after administration (40% inhibition) of the initial dose. The maximum effect (60% suppression of aggregation) develops after 4-7 days of constant admission in a dose of 50-100 mg / day. Antiaggregant effect persists throughout the life span of platelets (7-10 days).

In the presence of an atherosclerotic lesion, the vessel interferes with the development of atherothrombosis regardless of the localization of the vascular process (cerebrovascular, cardiovascular or peripheral lesions).

Indications

- prevention of atherothrombotic complications in adult patients with myocardial infarction (with a duration of several days to 35 days), ischemic stroke (with a duration of 7 days to 6 months) or occlusive disease of peripheral arteries;

- prophylaxis of atherothrombotic complications in adult patients with acute coronary syndrome with ST segment elevation with the possibility of performing thrombolytic therapy (in combination with acetylsalicylic acid);

- prevention of atherothrombotic complications in adult patients with acute coronary syndrome without ST segment elevation (unstable angina, myocardial infarction without Q wave), incl. in patients undergoing stenting (in combination with acetylsalicylic acid);

- prevention of atherothrombotic and thromboembolic complications, including stroke, in atrial fibrillation in adult patients with at least one risk factor for vascular complications that can not take indirect anticoagulants and have a low risk of bleeding (in combination with acetylsalicylic acid).